Intellia secures $400M non-dilutive credit facility with OrbiMed; $75M funded upfront

Intellia Therapeutics, Inc.

$75M funded at closing; up to $325M additional tied to milestones (FDA approval of lonvo-z, revenue targets, equity raise, mutual agreement).
Interest at SOFR + 6.15% (3% floor), maturity Sept 4, 2031; secured by substantially all assets incl. IP.
Proceeds for working capital and general corporate purposes; covenants include maintaining $50M liquidity until FDA approval of lonvo-z.
Facility provides flexibility for lonvo-z launch in HAE and pipeline advancement; TD Cowen advised Intellia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.